Alnylam
Alnylam, Biogen show gene-silencing data for Alzheimer’s therapies
This week, Alnylam and Biogen took a significant step toward redefining the landscape of Alzheimer’s disease treatment by revealing promising ...
Alnylam gives up on Onpattro’s US expansion after FDA rejects its rare heart disease indication
Despite receiving an endorsement from an advisory committee, the FDA has reached a different conclusion regarding the benefit-risk profile of ...
FDA Approves Novo Nordisk’s Rivfloza, Setting Stage for Market Duel with Alnylam
Novo Nordisk, known for its popular obesity therapy Wegovy, has achieved a significant milestone with the FDA approval of Rivfloza, ...
Pfizer’s tafamidis faces competition from Alnylam and BridgeBio in rare disease market
Alnylam and BridgeBio are poised to enter the highly lucrative transthyretin amyloidosis cardiomyopathy (ATTR-CM) market with the backing of an ...
FDA panel backs Alnylam’s Onpattro for rare heart condition despite small benefit
After facing doubts from the FDA regarding the expansion of its RNA-silencing drug Onpattro into the treatment of transthyretin amyloidosis ...
FDA doubts Onpattro’s benefit in heart disease, Alnylam faces Pfizer hurdle
The FDA has raised significant concerns about Alnylam’s attempt to expand the use of Onpattro for the treatment of transthyretin ...
Roche & Alnylam partner: Hypertension RNAi Therapy – Zilebesiran
Source – Roche Roche has recently unveiled an exciting collaboration with Alnylam to jointly develop and commercialize zilebesiran, a promising ...
